Osteoblast precursors from human embryonic stem cells

• US 20050282274A1
• Filed: 08/16/2005
• Published: 12/22/2005
• Est. Priority Date: 07/06/2001
• Status: Abandoned Application

• Current Assignee: Asterias Biotherapeutics Incorporated (Lineage Cell Therapeutics, Inc.)
• Original Assignee: Asterias Biotherapeutics Incorporated (Lineage Cell Therapeutics, Inc.)
• Inventors: Thies, R. Scott, Xu, Chunhui
• Application Number:
  US11/205,433
• Publication Number:
  US 20050282274A1
• Time in Patent Office: Days
• US Class Current: 435/366
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: C12N 2500/14 Calcium; Ca chelators; Calcitonin
• CPC Class Codes: C12N 2500/38 Vitamins
• CPC Class Codes: C12N 2500/44 Thiols, e.g. mercaptoethanol
• CPC Class Codes: C12N 2501/15 Transforming growth factor beta (TGF-β)
• CPC Class Codes: C12N 2501/155 Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
• CPC Class Codes: C12N 2501/39 Steroid hormones
• CPC Class Codes: C12N 2501/999 Small molecules not provided for elsewhere
• CPC Class Codes: C12N 2503/02 Drug screening
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 2506/04 from germ cells
• CPC Class Codes: C12N 2510/00 Genetically modified cells
• CPC Class Codes: C12N 2510/04 Immortalised cells
• CPC Class Codes: C12N 5/0654 Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
• CPC Class Codes: C12N 5/0662 Stem cells

Abstract

This invention provides populations of mesenchymal cells obtained from pluripotent stem cells by differentiating them ex vivo. Multipotent mesenchymal cells can in turn be differentiated into more specialized cell types such as osteoblasts, with properties that make them suitable for reconstituting musculoskeletal cell function in an individual. The compositions, methods, and techniques described in this disclosure can be used for a variety of commercially important diagnostic, drug screening, and therapeutic applications.

Claims

1. A set of two isolated cell populations for generating human osteoblast lineage cells, consisting of:

a first cell population comprising pluripotent stem (pPS) cells isolated from a human blastocyst, and

a second cell population that proliferates in culture, comprising at least ˜

30% pPS derived osteoblasts or osteoblast precursors, identifiable by the criteria that they are progeny of said pPS cells, and have at least one of the following characteristics;

they express osteonectin

they express osteocalcin

they form an extracellular matrix comprising calcium when cultured in vitro.

2. The set of cell populations of claim 1, wherein the osteoblasts or osteoblast precursors express both osteocalcin and type 1 collagen.

3. The set of cell populations of claim 1, wherein the osteoblasts or osteoblast precursors have increased alkaline phosphatase activity when cultured with bone morphogenic protein.

4. The set of cell populations of claim 1, wherein the osteoblasts or osteoblast precursors form an extracellular matrix comprising calcium when cultured in vitro.

5. The set of cell populations of claim 1, wherein the osteoblasts or osteoblast precursors have at least five of the following features:

they have morphological characteristics of osteoblast lineage cells, and they express osteocalcin, osteonectin, type 1 collagen, BMP receptors, PTH receptors, and CD105 (endoglin).

6. The set of cell populations of claim 1, wherein the osteoblasts or osteoblast precursors cause remineralization of bone.

7. The set of cell populations of claim 1, wherein the second cell population has been obtained by differentiating the pPS cells or progeny thereof in a medium containing a bone morphogenic protein (BMP), a ligand for a human TGF-β

receptor, or a ligand for a human vitamin D receptor.

8. The set of cell populations of claim 1, wherein the second cell population has been obtained by differentiating the pPS cells or progeny thereof in a medium containing dexamethasone, ascorbic acid, and β

-glycerophosphate.

9. The set of cell populations of claim 1, wherein the second cell population has been obtained by differentiating the pPS cells or progeny thereof in a medium containing BMP-4.

10. The set of cell populations of claim 1, wherein the second cell population has been genetically altered to express telomerase reverse transcriptase.

11. The set of cell populations of claim 1, wherein the second cell population has been genetically altered to express a bone morphogenic protein.

12. The set of cell populations of claim 1, wherein the pPS cells are a line of human embryonic stem cells.